

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: ChromedX Corp. (the "Issuer").

Trading Symbol: CHX

Number of Outstanding Listed Securities: 54,783,097

Date: August 5, 2016

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

ChroMedX Corp. has developed a proof-of-concept prototype of the company's HemoPalm analyzer and associated cartridge for measuring co-oximetry and bilirubin.

The prototype analyzer uses the same light source and spectrophotometer that will be used in the final HemoPalm analyzer, and the prototype cartridge is consistent with the optical chamber of the final HemoPalm cartridge.

2. Provide a general overview and discussion of the activities of management.

The Issuer's management was involved with ongoing operations with the HemoPalm and the AUF, and with identifying and meeting with potential joint venture partners both development and marketing

The HemoPalm development program continues with the development of prototype cartridges and spectroscopic measurements and the Company has commenced testing on the key spectroscopic component of the analyzer of HemoPalm blood analysis device.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date

instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None

- 14. Provide details of any securities issued and options or warrants granted.**

None

- 15. Provide details of any loans to or by Related Persons.**

None

- 16. Provide details of any changes in directors, officers or committee members.**

During the month, the Company appointed Ash Kaushal as the company's new president and chief executive officer.

Mr. Kaushal has over 25 years of experience in product development in the medical, defence, safety and nuclear industries. Mr. Kaushal has held vice-president and senior-level management positions with several Canadian and British corporations throughout his career including NIR Science Corp. and NIR Diagnostics Corp. in Campbellville, Ont., CME Telemetry in Waterloo, Indal Technologies in Mississauga, Ont., and several companies based in England, United Kingdom. Mr. Kaushal has developed hand-held products from initial concept right through to Food and Drug Administration submission. In these positions he had responsibility for research, engineering, quality assurance and clinical trials.

Mr. Kaushal will be responsible to lead, co-ordinate and oversee the complete development of the HemoPalm product line and other medical device products that his team is pursuing.

Mr. Kaushal takes over from Wayne Maddever at a critical stage in the company's development of a fully operational prototype of its patent-protected HemoPalm technology. Mr. Maddever has stepped down as an officer and director of ChroMedX and the company expresses its gratitude for his work with ChroMedX since its inception in 2013.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

There are no regulatory or political trends that affect the issuer. There is a trend to growth in the medical Point of Care market.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 5, 2016.

Ash Kaushal
**Name of Director or Senior
Officer**

"Ash Kaushal"
Signature

CEO
Official Capacity

Issuer Details Name of Issuer ChromedX Corp.		For Month End July 2016	Date of Report YY/MM/D 2016/08/03
Issuer Address Suite 520, 65 Queen St. West			
City/Province/Postal Code Toronto, ON M5H 2M5		Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name Ash Kaushal		Contact Position CEO	Contact Telephone No. 647-872-9982
Contact Email Address akaushal@chromedx.com		Web Site Address http://www.chromedX.com	

FORM 7 – MONTHLY PROGRESS REPORT